Serum KL-6 concentrations as a novel biomarker of severe COVID-19.
COVID-19
KL-6
biomarker
prognosis
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
07
05
2020
revised:
25
05
2020
accepted:
26
05
2020
pubmed:
30
5
2020
medline:
22
12
2020
entrez:
30
5
2020
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2-induced direct cytopathic effects against type I and II pneumocytes mediate lung damage. Krebs von den Lungen-6 (KL-6) is mainly produced by damaged or regenerating alveolar type II pneumocytes. This preliminary study analyzed serum concentrations of KL-6 in patients with coronavirus disease (COVID-19) to verify its potential as a prognostic biomarker of severity. Twenty-two patients (median age [interquartile range] 63 [59-68] years, 16 males) with COVID-19 were enrolled prospectively. Patients were divided into mild-moderate and severe groups, according to respiratory impairment and clinical management. KL-6 serum concentrations and lymphocyte subset were obtained. Peripheral natural killer (NK) cells/µL were significantly higher in nonsevere patients than in the severe group (P = .0449) and the best cut-off value was 119 cells/µL. KL-6 serum concentrations were significantly higher in severe patients than the nonsevere group (P = .0118). Receiver operating characteristic analysis distinguished severe and nonsevere patients according to KL-6 serum levels and the best cut-off value was 406.5 U/mL. NK cell analysis and assay of KL-6 in serum can help identify severe COVID-19 patients. Increased KL-6 serum concentrations were observed in patients with severe pulmonary involvement, revealing a prognostic value and supporting the potential usefulness of KL-6 measurement to evaluate COVID-19 patients' prognosis.
Identifiants
pubmed: 32470148
doi: 10.1002/jmv.26087
pmc: PMC7283867
doi:
Substances chimiques
Biomarkers
0
MUC1 protein, human
0
Mucin-1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2216-2220Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Eur J Clin Invest. 2020 Apr 20;:e13242
pubmed: 32307698
Arthritis Res Ther. 2019 Feb 14;21(1):58
pubmed: 30764869
J Med Virol. 2020 Oct;92(10):2216-2220
pubmed: 32470148
Intern Med. 2009;48(4):195-202
pubmed: 19218768
Eur Respir J. 2004 Jan;23(1):142-5
pubmed: 14738246
Respir Investig. 2019 May;57(3):290-291
pubmed: 30799155
Minerva Med. 2020 May 14;:
pubmed: 32407057
Intern Emerg Med. 2020 Oct;15(7):1247-1254
pubmed: 32078140
J Infect Chemother. 2019 Dec;25(12):936-942
pubmed: 31186197
J Med Virol. 2009 Dec;81(12):2104-8
pubmed: 19856476
Clin Exp Med. 2020 May;20(2):207-216
pubmed: 31970550
Eur J Pediatr. 2001 Jul;160(7):425-9
pubmed: 11475580